Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 See also  




2 References  













CBS-0550






●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

CBS-0550
Identifiers

  • N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide

CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23F4N3O
Molar mass397.418 g·mol−1
3D model (JSmol)

  • C3CC3Cn1c(cc(C(C)(C)C)n1C)=N\C(=O)c2cccc(C(F)(F)F)c2F

  • InChI=1S/C20H23F4N3O/c1-19(2,3)15-10-16(27(26(15)4)11-12-8-9-12)25-18(28)13-6-5-7-14(17(13)21)20(22,23)24/h5-7,10,12H,8-9,11H2,1-4H3/b25-16+

  • Key:PABOWKPYVAFTRN-PCLIKHOPSA-N

CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]

See also[edit]

References[edit]

  1. ^ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al. (February 2008). "Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action". Bioorganic & Medicinal Chemistry. 16 (3): 1111–24. doi:10.1016/j.bmc.2007.10.087. PMID 18006322.
  • ^ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al. (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.
    • Stub icon

    This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=CBS-0550&oldid=1083017936"
    Categories: 
    ●Cannabinoids
     ●Tert-butyl compounds
     ●Cyclopropanes
     ●Fluoroarenes
     ●Trifluoromethyl compounds
     ●Pyrazoles
     ●Cannabinoid stubs
     Hidden categories: 
    ●Articles with short description
     ●Short description matches Wikidata
     ●Articles without EBI source
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugs with no legal status
     ●Articles containing unverified chemical infoboxes
     ●All stub articles
      


    ●This page was last edited on 16 April 2022, at 14:18 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki